Dr. Levin has been in the private practice of urology since 1995. His special interests include minimally invasive treatments for prostate cancer including high intensity focused ultrasound (HIFU) and brachytherapy, stone disease and minimally invasive treatment for benign prostatic hyperplasia (BPH), including Rezūm®.
Dr. Levin was named a Rezūm Center of Excellence in January 2020. He is only the second Rezūm Center of Excellence in the U.S. and the first in the Northeast and Mid-Atlantic regions. He has performed more than 300 Rezūm procedures for men with BPH. He also received the Greenlight Center of Excellence designation for his high degree of experience performing GreenLight laser therapy for the treatment of BPH.
Dr. Levin participated in the clinical trial evaluating the Rezūm® System to treat BPH/enlarged prostate as part of the Rezūm II clinical study. He is one of only a few urologists in the Mid-Atlantic region currently offering this treatment, which is a new treatment option in the BPH clinical continuum of care. The system received FDA 510(k) clearance in September 2015 for the treatment of BPH. The Rezūm System is based on the Convective Water Vapor Energy (WAVE™) technology platform to treat a variety of endourological conditions beginning with BPH. The system uses radiofrequency energy to create sterile water vapor, or steam, to convectively deliver targeted, precise thermal energy treatments in a simple procedure with minimal discomfort, and provide improvements in urine flow and quality of life.
Dr. Levin was one of several authors of “PII-LBA1 Using the Thermal Energy of Convectively Delivered Water Vapor for the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: The Rezum II Study,” published in the Journal of Urology (J. of Urology), April 2016.
A member of the American Urological Association, the American Medical Association, and a fellow of the American College of Surgeons, Dr. Levin authored a chapter in Haskells Cancer Treatment on bladder, ureteral and renal pelvic malignancies.
In 2018, Dr. Levin passed the Certified Principal Investigator exam for clinical research trials.